INS and metabolic disease: In preclinical models and clinical trials, intermittent treatment with senolytics effectively prevented or alleviated cancers, cardiovascular, liver, kidney, and metabolic disorders [50–52], enhanced cardiac and vascular function in aging mice [52], augmented insulin sensitivity, and reduces adipose tissue inflammation in genetically obese mice [51].